Proposed patient selection criteria:
Complicated MSSA bloodstream infection in haemodialysis patients.

1. Persistent positive blood cultures after 48-72 hours appropriate antibiotic treatment
2. Persistent fever >72 hours into appropriate antibiotic treatment
3. Evidence of endocarditis / septic thrombophlebitis
4. Evidence of bone infection
5. Skin / soft tissue infection (e.g. diabetic foot)

On advice from microbiology only

Dose : 2g three times a week for 6 weeks

• Cefazolin SPC.pdf

​​Liposomal Amikacin sulphate​ (​​Arikayce​) Approved at NEL FPG for​​ non-tuberculous mycobacterial pulmonary disease (NTM-PD) caused by Mycobacterium avium complex (MAC)​ for adults and post pubescent children. 

​​590mg nebuliser dispersion vials​ 

Commissioning Policy NHSE  221007P

• Commissioning Policy NHSE 221007P

For how to access to Microguide app open poster below or follow link

• link to app
• Microguide poster updated october 2017.pptx

see attached

• Penicillin allergy poster 2016.pdf
• 4003 Pharmacy-Pennicillin-poster SMALL A4 March16.pdf
• Prescribing in Penicillin Allergy 2013.pdf

Approved for the treatment of Carbapenemase-producing organism confirmed inections, for which other antibiotic options are unsuitable due to allergy, adverse effects or resistance. Hospital ONLY 

Switch from nitrofurantoin liquid to nitrofurantoin tablets

As part of the Trust cost improvement programme, Pharmacy will no longer procure nitrofurantoin liquid and is now non-formulary, effective from 1^st May 2019. Nitrofurantoin tablets are still available.  Patients requiring administration as a liquid can disperse the tablets in 10mL water for 5 minutes giving a bright yellow fine dispersion that flushes easily without blockage¹.

Please contact your clinical pharmacy teams if you have any queries relating to this.

Reference

1. Handbook of Drug Administration via Enteral Feeding Tubes accessed via https://www.medicinescomplete.com/#/content/tubes/c275?hspl=nitrofurantoin on 8.5.2019

Flucytosine tablets approved via chairs action as an alternative to Flucytosine IV which is on formulary as an in tariff drug, but has been discontinued. It is bioequivalent to the intravenous preparation.

Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab approved at NEL FPG for treating COVID-19.

Formulary Status: Hospital or specialist centre (CMDU) only

• NICE TA 878

Paxlovid® (nirmatrelvir and ritonavir) 150mg/100mg tablet Approved at NEL FPG for treatment of COVID-19 in children 12 – 18 years old in the
COVID Medicines Delivery Unit (CMDU)

Formulary Status: Hospital ONLY (to be prescribed only by the CMDU)

Aproved at DTC for Corona virus, genotyping required to check if not omicrom variant so to give Ronapreve. If omicrom variant give Sotrovimab

For Continuation Only

Maribavir approved at NEL FPG for treating refractory cytomegalovirus infection after transplant in line with NICE TA 860.

• NICE TA 860

At the Trust we use valganciclovir for the treatment of CMV in renal patients.
If patients are not absorbing orally or the viral count is not reducing then IV ganciclovir will be used.
Foscarnet is reserved for resistant CMV.

Bulevirtide approved at NEL FPG for treating chronic hepatitis D in line with NICE TA.

Hospital Only

• NICE TA 896